The extracellular signal-regulated kinase (ERK) pathway plays an important role during the development and activation of B lymphocytes. We have recently shown that B-Raf is a dominant ERK activator in B-cell antigen receptor signalling. We now show that B-Raf is hyperphosphorylated upon BCR engagement and undergoes a prominent electrophoretic mobility shift. This shift correlates with ERK activation and is prevented by the MEK inhibitor U0126. Syk-deficient DT40 B cells display neither dual ERK phosphorylation nor a mobility shift of B-Raf upon BCR engagement. The inducible expression of a constitutively active B-Raf in this mutant line restores dual ERK phosphorylation and the mobility shift of endogenous B-Raf, indicating that these two events are connected to each other. By site-directed mutagenesis studies, we demonstrate that the shift is due to an ERK2-mediated feedback phosphorylation of serine/threonine residues within an evolutionary conserved SPKTP motif at the C-terminus of B-Raf. Replacement of these residues by negatively charged amino acids causes a constitutive mobility shift and a reduction of PC12 cell differentiation. We discuss a model in which ERK-mediated phosphorylation of the SPKTP motif is involved in negative feedback regulation of B-Raf.
Introduction
The ERK signalling pathway, which is involved in multiple physiological and pathological processes, is activated by a variety of plasma membrane-associated receptors through the activation of the small GTPase Ras (Ras-GTP). Ras-GTP binds to serine/threonine kinases of the Raf family (MAPKKK) and recruits them to the plasma membrane (Kolch, 2000) . Subsequently, Raf activates the dual-specificity kinases MEK1, 2 (MAPKK), which in turn phosphorylate the ERK1, 2 kinases (MAPK) at both threonine and tyrosine residues at a 'TEY motif' within the activation loop. This dual phosphorylation is correlated with ERK activity and, therefore, the extent of dual ERK phosphorylation can be used for indirect quantification of ERK activation (Yung et al., 1997) . Activated ERK shuttles into the nucleus where it modulates the activity of transcription factors by serine/threonine phosphorylation (Treisman, 1996) . Activated ERK also phosphorylates substrates in the cytoplasm, which contributes to the pleiotropic effects of ERK pathway signal transduction (Grewal et al., 1999) .
The strength and duration of signals processed through the ERK pathway are regulated by its upstream elements, in particular by members of the Raf-family (Marshall, 1995; York et al., 1998) . Three different Raf isoforms, A-Raf, B-Raf and Raf-1 have been identified in mammals (Hagemann and Rapp, 1999) . So far only Raf-1 and B-Raf have been identified in birds, where they are designated as c-Mil and c-Rmil, respectively (Koenen et al., 1988; Calogeraki et al., 1993) . For simplicity, we refer here to c-Rmil as B-Raf. Whereas Raf-1 is ubiquitously expressed, B-Raf exhibits a more restricted expression pattern (Barnier et al., 1995) . However, the Raf isoforms not only differ in their expression pattern but also in their function (Mercer and Pritchard, 2003) . B-Raf-deficient mice display an embryonic lethal phenotype, which suggests a nonredundant role for B-Raf beyond midgestation (Wojnowski et al., 2000) . In PC12 cells, signals processed through B-Raf result in sustained ERK pathway activation and cellular differentiation, whereas those processed through Raf-1 lead to transient ERK activation and cellular proliferation (York et al., 1998; Kao et al., 2001 ). This observation is, at least in part, explained by the fact that B-Raf displays a higher intrinsic kinase activity and a stronger affinity towards MEK than Raf-1 (Papin et al., 1998) . Furthermore, gain-of-function mutations in the human B-raf gene have been recently identified in about 70% of melanomas and, albeit to a lower frequency, in other tumors implicating B-Raf as an attractive target for antineoplasmic therapies (Davies et al., 2002) .
All Raf isoforms share three highly conserved regions (CR) forming distinct domains. The N-terminal half of these proteins contains the regulatory CR1 and CR2 domains, which are involved in Ras-GTP and 14-3-3 protein binding, respectively, and mediate the autoinhibition of Raf (Kolch, 2000) . Therefore, N-terminal deletion of CR1 and CR2 domains results in constitutive kinase activity and generates an oncoprotein (Heidecker et al., 1990) . CR3 contains the kinase domain and is followed by a C-terminal variable region.
Upon activation, Raf-1 is phosphorylated on serine, threonine and tyrosine residues, which fulfill regulatory functions (Chong et al., 2001) . Some regulatory serine and threonine residues are shared between B-Raf and Raf-1; however, the phosphorylation status of these residues can differ between them. For example, upon extracellular stimulation, Raf-1 becomes phosphorylated at serine 338 contributing to its full activation, whereas the constitutive phosphorylation of the equivalent position in B-Raf contributes to its high basal kinase activity (Mason et al., 1999; Brummer et al., 2002; Carey et al., 2003) . Thus, the analysis of the individual phosphorylation sites of each Raf isoform and the mechanisms leading to their phosphorylation provide more insight into the isoform-specific regulation of the different Raf kinases.
Engagement of the B-cell antigen receptor (BCR) generates a multitude of signals, which control the development and activation of B lymphocytes (Kurosaki, 1999) . The first BCR signals involve the activation of protein tyrosine kinases (PTK) like Syk and Lyn, and the phosphorylation of their substrates. Some of these signals are then further processed through mitogen-activated protein kinase (MAPK) cascades like the ERK pathway (Hashimoto et al., 1998; Jiang et al., 1998; Shirakata et al., 1999; Gold, 2000) . The ERK pathway is implicated in transmitting positive selection signals during B lymphopoiesis, and in the regulation of B-cell effector functions (Iritani et al., 1997; Fleming and Paige, 2001; Richards et al., 2001) . However, the mechanism underlying the coupling of antigen receptors to the ERK pathway and the means limiting the extent of ERK activity await further characterization. Previously, only Raf-1 has been implicated in BCR-mediated ERK pathway activation (for review see Gold, 2000) . However, by using an inducible gene deletion approach in chicken DT40 B cells, we demonstrated that B-Raf has an important function for the maintenance of basal ERK activity as well as for an efficient BCR-mediated ERK activation (Brummer et al., 2002) . Here we report that, upon BCR engagement, B-Raf is subject to a feedback phosphorylation by activated ERK, and we have determined these phosphorylation sites at the unique C-terminal region of B-Raf.
Results

BCR engagement induces phosphorylation and an electrophoretic mobility shift of B-Raf
Stimulation of chicken DT40 B cells with anti-IgM antibodies results in rapid phosphorylation of PTK substrates of 80 and 70 kDa (Figure 1 ). BCR engagement also provokes a rapid, maximum increase of dual phosphorylation of ERK2 (Figure 1 ), the predominantly expressed ERK isoform in DT40 cells. The first signalling elements of the ERK kinase cascade are members of the Raf kinase family. Besides Raf-1, DT40 B cells clearly express B-Raf as a 95 kDa protein ( Figure 1a ) and inducible gene deletion experiments in DT40 have demonstrated a more important role for BRaf in BCR-mediated ERK activation than for Raf-1 (Brummer et al., 2002) . The analysis of B-Raf in the total lysates of anti-IgM-stimulated DT40 cells showed that the amount of detectable B-Raf decreased in parallel with increasing phosphorylation of PTK substrates and ERK2 (Figure 1, second panel) . Among other possibilities, the reduction in the amount of B-Raf could be due to phosphorylation of B-Raf, which would hamper its recognition by the C-19 anti-B-Raf antibodies raised against a 19 amino-acid long C-terminal sequence of human B-Raf. Indeed, the C-19 epitope carries putative phosphorylation sites for proline-directed Ser/Thr-kinases ( Figure 3a ). To test this possibility, triplicates of total lysates from unstimulated or stimulated DT40 cells were analysed for B-Raf detection by Western blotting. Prior to development with C-19 anti-B-Raf antibodies, the membrane was either incubated with l-PPase buffer only (Figure 2a , first panel) or with l-PPase (Figure 2a, second panel) . The l-PPase is a broad-specificity protein phosphatase that dephosphorylates all types of phosphorylated amino acids (Zhuo et al., 1993) . A second, slower migrating form of B-Raf is detected by C-19 antibodies in the lysates derived from anti-IgM-stimulated DT40 cells (Figure 2a , first panel). This form is far more efficiently detected after treatment of the membrane with l-PPase (Figure 2a , second panel). The third Western blot membrane was probed with anti-B-Raf H-145 antibodies, raised against the unique N-terminal region of human B-Raf (Figure 2a, third panel) . The H-145 antibodies detect Figure 1 Phosphorylation and activation of B-Raf in DT40 cells by BCR engagement. Western Blot analysis (10% SDS-PAGE) of total cell lysate (TCL) of DT40 cells stimulated with anti-IgM antibody M4 for the indicated times. PTK substrates were detected with antiphosphotyrosine antibody (anti-pY) and B-Raf was detected by anti-B-Raf C-19 antibodies, which are raised against the C-terminus of human B-Raf. ERK2 and dual-phosporylated ERK were detected by anti-ERK2 and anti-pERK antibodies, respectively
Identification of B-Raf as a novel ERK substrate T Brummer et al both the faster and slower migrating B-Raf species more efficiently than C-19 antibodies. Taken together, these data suggest that BCR engagement on DT40 cells results in phosphorylation of B-Raf accompanied by an electrophoretic mobility shift of the protein and hampered recognition of B-Raf by the C-19 antibodies. This mobility shift is not only detected in the chicken B-cell line DT40 but also in the murine K46 B-cell lymphoma line and the human Burkitt lymphoma cell line Ramos (Figure 2b ). Note that K46 and all other murine B cells (data not shown) express two size forms of B-Raf, whereas in unstimulated chicken and human B cells only one major B-Raf form is present. The two BRaf subtypes in murine B cells are most likely generated by alternative splicing of exons coding for the linker region between CR2 and CR3 (Barnier et al., 1995) .
Interestingly, anti-B-Raf C-19 antibodies detect BRaf from unstimulated and anti-IgM-stimulated Ramos B cells with equal efficiency (data not shown). Since the C-terminal 19 amino acids between chicken and human B-Raf differ by one amino acid, the discrimination by anti-B-Raf C-19 antibodies between different phosphorylation states may depend on the amino-acid sequence of the C-terminus. This might explain why the inefficient detection of B-Raf in lysates from activated mammalian cells has not been reported in previous studies using anti-B-Raf C-19 antibodies.
The C-terminus of B-Raf carries a conserved ERKphosphorylation motif
The inefficient detection of the C-19 antibodies to B-Raf isolated from stimulated cells is likely caused by phosphorylation of the C-19 epitope. Thus, the Cterminus of B-Raf was screened for consensus phosphorylation motives. Indeed, the C-19 epitope carries the sequence SPKTP that is a bona fide ERKphosphorylation motif (P-X-S/T-P). The serine and threonine in the SPKTP sequence are both followed by a proline and thus fulfill the minimal requirements (S/T-P) for phosphorylation by ERK (Songyang et al., 1996) . The SPKTP motif is conserved in all known vertebrate B-Raf orthologues (Figure 3a) , and has also been found in the B-Raf genes of the teleosts Fugu rubripes and Danio rerio, which were retrieved using data provided freely by the Fugu genome consortium (http://bahama.jgi-psf-org) and the zebrafish information network (http://zfin.org), respectively (data not shown). In addition, the SPKTP motif is found at a homotopic position of D-Raf, the Raf kinase of Drosophila melanogaster (Sprenger et al., 1993) . None of the known Raf-1 and A-Raf orthologues contain the SPKTP motif, whereas all Raf kinase family members carry the C-terminal 14-3-3-binding motif RSASEP (Figure 3a) .
Many ERK substrate proteins carry a kinase interaction motif (KIM) with the consensus sequence ( et al., 2000) , which facilitates the contact between ERK and its substrate. Interestingly, the C-termini of all known B-Raf orthologues carry a putative KIM (Figure 3a) in the vicinity of a bona fide ERK phosphorylation motif, strongly suggesting that the C-terminus of B-Raf is phosphorylated by an ERK kinase. In order to clarify this notion, we purified B-Raf from unstimulated DT40 cells and performed an in vitro ERK-kinase assay (Figure 3b ). The presence of both active ERK2 and ATP, but not that of ATP alone, induces a mobility shift of B-Raf, which is similar to that found in BCR-stimulated DT40 cells (Figure 3b , compare lanes 4 and 8). This suggests that the mobility shift is caused by the phosphorylation of B-Raf by ERK rather than by an autophosphorylation. Figure 1 were separated on an 8% SDS-PAGE and transferred to a membrane. Subsequently, the membrane was cut into three identical pieces. Prior to the detection with anti-B-Raf C-19 antibodies, the membranes were either incubated with buffer alone (top panel) or with 4000 U l-PPase (middle panel). As a control, the third membrane was developed with anti-B-Raf H-145 antibodies recognizing the N-terminus of B-Raf. To determine precisely which amino acid(s) in the SPKTP sequence of B-Raf become phosphorylated by ERK, we constructed an expression vector encoding a chimeric protein consisting of the enhanced green fluorescent protein (EGFP) and a 95 amino-acid long C-terminal sequence of B-Raf. We designate this fusion protein as EGFP/B-RafCT. By site-directed mutagenesis, we introduced mutations into the EGFP/B-RafCT vector, such that the serine and/or threonine in the SPKTP sequence are replaced by alanine. The vectors for mutant or wild-type EGFP/B-RafCT were transfected into COS-7 cells and the transiently expressed fusion proteins were immunopurified with anti-EGFP antibodies. As a control, the same procedure was done with COS-7 cells transiently expressing only EGFP. The purified proteins were incubated with [g-33 P]ATP in the absence or presence of recombinant, activated ERK2.
The proteins were then size-separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and phosphorylated proteins were detected by autoradiography ( Figure 4a ). ERK2 phosphorylates the EGFP/B-RafCT fusion protein as long as either the serine or the threonine of the SPKTP sequence is present ( Figure 4a , lanes 6, 12 and 15). The EGFP/B-RafCT fusion protein with a double mutation (APKAP) of the SPKTP sequence and EGFP proper are not labelled by [g- 33 P]ATP ( Figure 4a , lanes 2, 3, 8 and 9). Thus, ERK2 specifically phosphorylates both serine and threonine of the SPKTP sequence and no other part of the EGFP/B-RafCT fusion protein. In the absence of ERK2, the EGFP/B-RafCT fusion proteins are not labelled, demonstrating that no copurified kinase is mediating the phosphorylation of the SPKTP sequence ( Figure 4a , lanes 1, 4, 7, 10 and 13). We next tested whether the EGFP/B-RafCT fusion proteins also display a mobility shift after their phosphorylation by ERK2. The purified fusion proteins were incubated with either buffer only (À) or with active ERK2 ( þ ), and detected on the Western blot membrane by an anti-GFP antibody ( Figure 4b ). The ERK2-mediated phosphor- (Beck et al., 1987) ), human Raf-1 (GenBank Accession number P04049 (Bonner et al., 1986) ), chicken c-Mil/Raf-1 (GenBank Accession number CAA30069 (Koenen et al., 1988) ), D-Raf (GenBank Accession number TVFFDF (Sprenger et al., 1993) ), human B-Raf (GenBank Accession number P15056 (Sithanandam et al., 1990) ), a computer-translated EST encoding a B-Raf orthologue from Xenopus laevis (GenBank Accession number BE026907) and chicken cRmil/B-Raf (GenBank Accession numbers X67052 (Calogeraki et al., 1993) and AF449458 (this work)) by MegAlign Software (DNASTAR) using Clustal method, and a PAM250 residue weight table. The ERK-phosphorylation motif (SPKTP), the 14-3-3 protein-binding motif (RSXSXP) (Yaffe et al., 1997) , lanes 2 and 6). Next, it was of interest if mutation of the SPKTP motif would affect the mobility shift of a full-length BRaf protein. Therefore, we cloned a full-length chicken B-Raf from a bursal cDNA library. Interestingly, we could not isolate any amplicon containing exon 10, suggesting that this exon is not part of a mature bursal B-Raf transcript and that, as was reported for murine tissues (Barnier et al., 1995) , expression of this evolutionary conserved exon is restricted to neuroectodermal tissues. Interestingly, Papin et al. (1998) have shown that the translated exon 10 sequence confers a higher basal activity to B-Raf and, thus, the omission of exon 10 in bursal B-Raf might be regarded as pretranslational mechanism to control B-Raf activity in B cells. This fulllength B-Raf cDNA devoid of exon 10 will be referred as bursal B-Raf cDNA (GenBank Accession number AF449458) in the following. Accordingly, we then introduced mutations into this cDNA such that the serine and threonine in the SPKTP sequence are replaced by alanine (APKAP). In order to mimic phosphorylation of the SPKTP motif, cDNAs encoding bursal B-Raf in which the phosphorylatable residues were replaced by either aspartate (DPKDP) or glutamate residues (EPKEP) were generated. These cDNAs were expressed as N-terminal hemagglutinine-tagged proteins (HA-B-Raf) in COS-7 cells. In contrast to HA-B-Raf SPKTP, the HA-B-Raf APKAP mutant does not display a prominent mobility shift in lysates of PVtreated cells (Figure 4c) . Conversely, the B-Raf mutants with a constitutive negatively charged C-terminus (HA-B-Raf DPKDP/EPKEP) already exhibit a prominent mobility shift in lysates from serum-starved cells. Together, our data show that the SPKTP motif is dual phosphorylated by ERK2 and that a negatively charged C-terminus is necessary and sufficient to confer the mobility shift of full-length B-Raf.
MEK inhibition prevents the electrophoretic mobility shift of B-Raf
Within this MAPK cascade, ERK2 is phosphorylated and activated by MEK. We next tested whether the Cterminal phosphorylation of B-Raf could be prevented in vivo by treating DT40 cells with the MEK-specific inhibitor U0126 (Favata et al., 1998) . DT40 cells were pretreated either with DMSO as vehicle control or with 50 mM U0126, and then stimulated for different times by BCR engagement. Treatment with U0126 does not affect PTK substrate phosphorylation in stimulated DT40 cells, whereas dual ERK phosphorylation was completely abolished (Figure 5a ). Pretreatment with U0126 significantly increased the detection of B-Raf by the C-19 antibodies (Figure 5a ) and inhibited the mobility shift of B-Raf (Figure 5b ). These data demonstrate that the mobility shift of B-Raf and phosphorylation of the C-19 epitope sequence are MEK-dependent, coinciding events.
Ectopic ERK activation results in feedback phosphorylation of B-Raf
Our finding that ERK phosphorylates B-Raf suggests that not only forward but also feedback signals occur within the B-Raf/MEK/ERK2 module. Thus, we asked whether or not the ERK-mediated phosphorylation of B-Raf requires a prior activation of B-Raf. To test this, we expressed a truncated, constitutively active form of B-Raf (DB-Raf) in DT40 cells. This form, which was isolated from a myeloma line, lacks the N-terminal regulatory domains and thus displays a high basal kinase activity (Misawa et al., in preparation). As constitutive expression of active Raf kinases can induce a phenotypic drift, we employed the MerCreMer (MCM) system (Zhang et al., 1996) for the inducible expression of DB-Raf. In the vector pAloxPDB-Raf, the open reading frame of DB-Raf is interrupted just after the start codon by a 423 bp loxP-STOP-pA-loxP insert, which prevents DB-Raf expression (Figure 6a ) and can be excised by MCM.
The pAloxPDB-Raf vector was transfected into DT40MCM cells constitutively expressing the 4-hydroxy-tamoxifen (4-HT)-regulated Cre recombinase MerCreMer. Cells from this double transfectant, DT40MCMiDB-Raf, were cultured for different times in 4-HT-containing medium, and stimulated by BCR engagement (Figure 6b) . A prominent DB-Raf expression is already detected 3.5 h after the start of the 4-HT treatment (Figure 6b, lanes 4-6) . At that time point, the dual ERK phosphorylation can still be increased by BCR engagement (Figure 6b, lanes 4-6) . At later time points (6-12 h), DT40MCMiDB-Raf cells reach a maximum of DB-Raf expression and display a strong dual ERK phosphorylation, which can no longer be enhanced by BCR engagement (Figure 6b, lanes 7-12) . Thus, the ERK pathway in DT40 cells can be activated by inducible expression of DB-Raf without any BCR engagement. In DT40 cells with maximal DB-Raf expression, the detection of endogenous B-Raf by the C19 antibodies decreases, indicating a phosphorylation of the SPKTP sequence (Figure 6b, lanes 7-12) . Indeed, 24 h after the start of the 4-HT treatment, a strong mobility shift of the endogenous B-Raf is detected prior to BCR engagement (Figure 6c, lane 4) . Taken together, these data show that the feedback phosphorylation of B-Raf only requires an active ERK and not the activation of upstream-situated signalling elements.
Previously, it has been shown that BCR-mediated ERK activation is blocked in Syk-deficient DT40 cells (DT40SykÀ/À; Jiang et al., 1998) . To test whether inducible DB-Raf expression could bypass this block, we generated DT40SykÀ/ÀMCMiDB-Raf cells. Upon BCR engagement, these cells do neither display a mobility shift of B-Raf nor a prominent dual ERK phosphorylation (Figure 7, lanes 2 and 3) . However, DB-Raf expression restores dual ERK phosphorylation and the mobility shift of endogenous B-Raf (Figure 7 , lanes 4-6).
Negative charges at the equivalent position of the SPKTP motif reduce the ability of B-Raf to promote PC12 cell differentiation Previous studies have shown that NGF-mediated differentiation of PC12 cells into sympathetic-like neurons is mediated by B-Raf through sustained ERK activation (Marshall, 1995; York et al., 1998) . Likewise, ectopic expression of signalling elements or oncoproteins mimicking NGF signalling can promote PC12 cell differentiation in the absence of NGF (Wood et al., 1993) . Hence, we asked to which extent bursal B-Raf, and in particular its mutants with a mutated SPKTPmotif, can promote PC12 cell differentiation. Therefore, PC12 cells were transfected with expression vectors encoding either wildtype HA-B-Raf or HA-B-Raf with a mutated SPKTP motif. For a better evaluation of the differentiation potential of bursal B-Raf proteins, PC12 cells were also transfected with expression vectors encoding catalytically inactive HA-B-Raf (K520W). As a positive control for neuronal differentiation, an 
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T Brummer et al expression vector encoding an EGFPDB-Raf fusion protein, which exhibits a comparable biological activity as DB-Raf (data not shown), was transfected. In line with the data showing DB-Raf as a potent ERK activator (Figure 6b ), EGFPDB-Raf behaves as a very potent inducer of neuronal differentiation (Figure 8a ). Although to a lesser extent than EGFPDB-Raf, wildtype HA-B-Raf also induces differentiation of PC12 cells. This is, to our knowledge, the first report that ectopic expression of a full-length B-Raf protein, which even lacks the neuron-specific exon 10, can induce neuronal differentiation in the absence of a neuritogenic stimulus like NGF. This degree of differentiation of HA-B-Raftransfected PC12 cells cannot be explained by spontaneous differentiation as a response to the transfection, as PC12 cells transfected with the empty vector or expression vectors encoding catalytically inactive HA-BRaf K520W or EGFP were generally indistinguishable from untransfected cells (Figure 8a ; data not shown). HA-B-Raf APKAP-expressing cells showed a similar degree of neuronal differentiation in comparison to those expressing HA-B-Raf SPKTP. Interestingly, PC12 cells expressing HA-B-Raf with a constitutively negative-charged C-terminus (DPKDP and EPKEP) showed a remarkable reduction in neuronal differentiation as compared to HA-B-Raf-expressing cells (Figure 8b ). The reduction between wildtype B-Raf (SPKTP) and the EPKEP mutant is more than 60% and is statistically significant (P-value ¼ 0.020-0.022). Very similar ratios were obtained when neuronal differentiation of HA-BRaf transfectants was augmented by the addition of EGF (100 ng/ml) to the culture medium, although the total numbers of differentiated cells were increased under these conditions (data not shown). Together, these data suggest that a phosphorylated and thereby negatively charged SPKTP motif reduces the biological activity of B-Raf.
Discussion
In the present study, we demonstrate that B-Raf is phosphorylated on a C-terminal SPKTP sequence by ERK. This feedback phosphorylation of B-Raf is detected in either BCR-stimulated or in DB-Raf-expressing B cells with ERK activation. We have demonstrated recently that B-Raf-deficient DT40 cells display a drastically reduced basal ERK activity as well as defects in the immediate early and late phases of BCRmediated ERK activation. This observation is in sharp contrast to the phenotype of Raf-1-deficient DT40 cells, which lack an apparent defect in basal and BCRmediated ERK activation (Brummer et al., 2002) . Thus, B-Raf may play an important role during B-cell activation and development, processes which involve the (BCR)-Ras-Raf-ERK signalling pathway (Iritani et al., 1997; Fleming and Paige, 2001 ). In Syk-deficient DT40 cells, no ERK2 phosphorylation is observed upon BCR engagement, indicating that Syk operates upstream of Raf-1 and B-Raf in BCR signalling (Figure 7) . Thus, despite the accumulating evidence that Raf-1 and B-Raf are differently regulated in B lymphocytes, their activation pathways share upstream signalling elements like Syk and Ras-GTP (Hashimoto et al., 1998; Brummer et al., 2002) . in Drosophila S2 cells, which could be blocked by RNAimediated ablation of MEK or ERK expression. Thus, the principle that an Raf-kinase is subject to a feedback phosphorylation by activated ERK has been conserved between Drosophila and vertebrates. Interestingly, the teleosts Fugu and Danio already possess two rafparalogues, B-Raf and Raf-1, but only the B-Raf orthologues carry a C-terminal SPKTP motif. Sequence comparisons propose that, as a result of gene duplication, the three mammalian raf paralogues have arisen from a single prototypic raf-gene. This implies that the SPKTP motif has been maintained in B-Raf, but has been lost during the evolution of the Raf-1 and A-Raf paralogues, and suggests that these phosphorylation sites are an isoform-specific characteristic for the regulation of B-Raf.
By phosphorylating the C-terminus of B-Raf, ERK initiates a feedback-signalling loop to its upstreamsituated activator (Figure 9 ). Feedbacks play an important role in the regulation of a signalling pathway, and can be either positive or negative in nature (Ferrell, 2002) . In the case of the MAPK cascade, several feedback regulation mechanisms have been discussed. For the ERK-mediated phosphorylation of Syk, a positive feedback has been proposed (Xu et al., 1999) . In contrast, a negative feedback phosphorylation of upstream signalling components by ERK has been described for SOS and Frs2a (Ueki et al., 1994; Dong et al., 1996; Lax et al., 2002) and suggested for MEK1 (Mansour et al., 1994) . A feedback regulation of Raf isoforms by ERK, the most downstream, invariant member of the ERK pathway, could permit an efficient regulation of the entire module. Indeed, although Raf-1 does not have the C-terminal ERK phosphorylation motif of B-Raf, it is also most likely phosphorylated by ERK at a yet unknown position (Anderson et al., 1991; Lee et al., 1992; Samuels and McMahon, 1994; Ferrier et al., 1997; Wartmann et al., 1997; Zimmermann et al., 1997) . The feedback phosphorylation of Raf-1 is not necessarily correlated with an increase of its kinase activity (Williams et al., 1993) and apparently reflects a negative feedback (Alessi et al., 1995; Wartmann et al., 1997) . Likewise, phosphorylation of the SPKTP motif by ERK could be a mechanism to adjust B-Raf activity in order to dampen the initial steep increase of ERKpathway activation following BCR engagement. Such a negative feedback loop is a particularly attractive model in the light of the high basal MAPKKK and transforming activities described for B-Raf in other cell types (Papin et al., 1998; Kao et al., 2001) . Indeed, PC12 cells expressing HA-B-Raf proteins with a constitutively negative-charged C-terminus display a reduced tendency for neuronal differentiation. These data imply that ERK-mediated phosphorylation of the SPKTP motif represents a negative feedback loop attenuating B-Raf activity in vivo. In this respect, it would be interesting to analyse how this negative feedback loop cooperates with other recently identified negative regulators of B-Raf like Akt/PKB and SGK (Guan et al., 2000; Zhang et al., 2001) . Indeed, the elucidation of the negative regulation of B-Raf would be of particular importance as gain-offunction mutations in the human B-Raf gene have been identified in about 70% of melanoma and to a lower frequency in other tumors (Davies et al., 2002) .
The dual phosphorylation of the SPKTP motif induces a strong mobility shift, likely indicating a conformational change of the B-Raf C-terminus. This ERK2-mediated conformational alteration may expose regulatory sequences of B-Raf and thereby influence its enzymatic or biological activity in vivo. For example, the SPKTP motif is just a 15 amino-acid C-terminal from the 14-3-3-binding site of B-Raf (Figure 3a) . A B-Raf protein with a mutation of this 14-3-3-binding site displays a dramatically reduced activity in vivo, presumably by preventing the efficient interaction of B-Raf with downstream effectors, but retains significant catalytic activity in vitro (MacNicol et al., 2000) . Likewise, we could not detect an apparent difference between the in vitro kinase activities of HA-B-Raf APKAP and HA-B-Raf EPKEP proteins (data not shown), and it is therefore quite likely that the consequence of SPKTP phosphorylation can be only assessed by in vivo experiments. Indeed, it is conceivable that the ERK2-mediated phosphorylation of the SPKTP motif may influence the binding of 14-3-3 adapter proteins and the coupling of the B-Raf kinase to its targets as well. Alternatively, the conformational alteration of the B-Raf C-terminus may not affect the kinase activity directly but may control the subcellular localization of B-Raf. In this regard, Wartmann et al. (1997) have demonstrated that activated Raf-1, hyperphosphorylated in an MEK-dependent manner, dissociates from the plasma membrane. This could result in the sequestration of Raf-1 from activators or effectors and could lead to ERK pathway downregulation in vivo. Studies on MAPK modules in different eucaryotic systems have shown that their components are assembled as preformed signalling complex modules, which ensure not only signalling specificity, but also allow rapid signal transduction across the module (Schaeffer and Weber, 1999) . B-Raf is complexed with MEK, Hsp90 and 14-3-3 proteins (Yamamori et al., 1995; Jaiswal et al., 1996; Papin et al., 1996) . In addition, ERK2 could be recruited to this complex by scaffold proteins like MP1 that bridges between MEK1 and ERK1 (Schaeffer and Weber, 1999) , and could be additionally tethered to B-Raf by interaction with its putative KIM. Indeed, such a preformed complex containing B-Raf and ERK2 was proposed to exist in neurons (Toran-Allerand et al., 1999) and future studies are required to analyse the stoichiometry, dynamics and stability of the B-Raf/MEK/ERK2 module. Nevertheless, our present data suggest that, upon BCR engagement, this B-Raf/MEK/ERK2 module is recruited and B-Raf is immediately regulated by activated ERK2 through phosphorylation of the SPKTP motif.
Materials and methods
Plasmid constructs
The expression vector pANMerCreMer (pANMCM) encoding the chimaeric Cre-recombinase MerCreMer (MCM) has been described previously (Zhang et al., 1996) . The coding sequence of DB-Raf (encoding the 378 C-terminal amino acids of B-Raf) was isolated from pMX-1DB-Raf (Misawa et al., in preparation) by EcoRI digestion, blunted and inserted into SmaI site of the vector ploxP-leader (Y Zhang and MR, unpublished) in order to obtain the expression cassette 'START-loxP-STOPpolyA-loxP-DB-Raf'. This cassette was subcloned into the EcoRV site of the expression vector pAN-H (Zhang et al., 1996) to generate pAloxPDB-Raf-neo. The neomycin-resistance gene of pAloxPDB-Raf-neo was replaced by a zeocinresistance gene cassette to obtain pAloxPDB-Raf-zeo. To construct an expression vector for EGFP-DB-Raf, the DB-Raf cDNA was subcloned into the SmaI site of pEGFPC-1 (Clonetech). For construction of expression vectors encoding for EGFP/DB-RafCT proteins, the 3 0 end of the DB-Raf coding region was amplified by PCR on pMX-1DB-Raf as a template. The 5 0 -oligonucleotide used for this PCR introduced a single-nucleotide exchange into the DB-Raf cDNA sequence, leading to a silent mutation and generation of an EcoRV site. The amplicon was subcloned into EcoRI-digested, blunted pEGFP-C1. The 5 0 end of the B-Raf part is equivalent to position 2170 on the chicken B-Raf cDNA (Calogeraki et al., 1993) .
A chicken B-Raf cDNA corresponding to exons 2-19 was cloned by PCR from an oligo-dT-primed bursal B-cell cDNA library (kindly provided by Dr Jean-Marie Buerstedde, Heinrich-Pette-Institut, Hamburg, Germany) as a template. Due to difficulties to amplify exon 1 from cDNA, this exon was cloned by PCR from a genomic c-Rmil/B-raf clone (kindly provided by A Eyche`ne (Calogeraki et al., 1993) ) in order to assemble a full-length bursal B-Raf cDNA. This cDNA was subcloned in the vector pFlu containing a Cytomegalovirus promotor and a bovine growth hormone polyadenylation site in order to achieve expression of a N-terminal hemagglutininetagged B-Raf (HA-B-Raf). A cDNA encoding catalytically inactive HA-B-Raf (HA-B-Raf(K520W)) was generated by replacing the codon for the ATP accepting lysine residue with the codon for tryptophan. All mutations introduced into EGFP-B-RafCT or bursal B-Raf expression vectors were introduced using the 'Quick change' site-directed mutagenesis kit (Stratagene). The sequence of all oligonucleotides used in this study can be obtained upon request. All mutated cDNA sequences were confirmed by DNA sequence analysis.
Cell lines, cell culture, transfections and immunofluorescence microscopy
Wildtype DT40 and Syk-deficient DT40 cells were a kind gift of Dr Tomohiro Kurosaki (Kansai Institute for Liver Research, Japan) and have been described (Klein et al., 1975; Takata et al., 1994) . DT40 and Ramos B cells were cultivated as described previously (Brummer et al., 2002) . To achieve an inducible expression of DB-Raf, DT40 cells or DT40SykÀ/À cells were first transfected with 10 mg of AhdI-linearized pANMCM. Stable transfectants were selected in the presence of 2 mg/ml hygromycin B. DT40 cells and DT40SykÀ/À cells expressing MCM are designated as DT40MCM and DT40SykÀ/ÀMCM in the following. DT40MCM and DT40SykÀ/ÀMCM were transfected with 10 mg ScaI-linearized pAloxPDB-Raf-neo or pAloxPDB-Rafzeo, respectively. Stable transfectants were selected in the presence of 2 mg/ml G418 or 1 mg/ml zeocin, respectively.
The K46 cells used in this study are a class switch variant (m/ k to g2a/k) of the originally described K46 cell line (Kim et al., 1979) , and were cultured as described for Ramos B cells. COS-7 cells were maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin/streptomycin, 2 mM glutamin, 50 mM b-mercaptoethanol and 10 mM HEPES in a 7.5% CO 2 atmosphere at 371C, and were transiently transfected with 10 mg plasmid DNA using the DEAE-dextran method (Bruyns et al., 1998) . PC12 cells were grown in DMEM supplemented with 5% FCS, 10% horse serum, 100 U/ml penicillin/ streptomycin, 2 mM glutamin, 50 mM b-mercaptoethanol, and 10 mM HEPES. PC12 cells (5 Â 10 5 cells/ml) were plated on coverslips and transfected with 3 mg plasmid DNA and 10 ml Gene Juice reagent (Novagen) according to the protocol supplied by the manufacturer. The medium was replaced 24 h after transfection by fresh medium and the cells were cultivated for another 48 h. Subsequently, the cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 min, followed by incubation with permeabilization solution (4% PFA) in PBST (PBS containing 0.2% Triton X-100) for 15 min. The cells were treated with blocking solution (10% FCS/PBST) for 30 min, followed by incubation with 4 mg/ml anti-HA antibody 12CA5 (Roche) for 1 h. After three washes with 2 ml PBST, the cells were incubated with 6.5 mg/ml Cy2-conjugated goat-antimouse IgG (Jackson Immunoresearch Laboratories) for 1 h, followed by four washes with PBST. The transfectants were identified by positive HA staining and neurite outgrowth was quantitated by scoring cells with neurites longer than the size of two cell bodies. In order to detect statistically significant differences between the neuritogenic potentials of the various HA-B-Raf mutants, the statistical test of analysis of variance (ANOVA) was performed using the statistical analysis software (SAS) from the SAS Institute, North Carolina, USA. Pairwise comparison was examined with Bonferronni adjustment. Nonparametric Wilcoxon test was used to confirm the result of the ANOVA analysis.
Induction of D-B-Raf expression by 4-HT treatment DT40 transfectants allowing an inducible expression of DBRaf were transferred to culture medium containing 200 nM 4-HT (Sigma), and grown for various times as indicated. DT40 or DT40MCM cells were exposed to 4-HT in the same manner to monitor for 4-HT side effects. A treatment with 200 nM 4-HT does not influence dual ERK and B-Raf phosphorylation (data not shown).
Antibodies
The rabbit anti-B-Raf polyclonal antibody C-19 (Santa Cruz Biotechnology) was raised against the C-terminal 19 aminoacid stretch of human B-Raf. The rabbit anti-B-Raf antibody H-145 (Santa Cruz Biotechnology) was raised against an N-terminal portion of human B-Raf (amino-acid position 20-145; Sithanandam et al., 1990) . ERK2 and dual-phosphorylated ERK were detected with anti-ERK2 clone 33 (Transduction Laboratories) and anti-activated MAPK 12D4 (Nanotools) antibodies, respectively. PTK substrates were detected with antiphosphotyrosine antibody 4G10 (Upstate Biotechnology). The antibody anti-BAP37 was kindly provided by Mitsuaki Kimura. The anti-chicken IgM monoclonal antibody M4 (Southern Biotechnology) was used for BCR engagement on DT40 cells. Human Ig-absorbed goat anti-mouse IgG (Southern Biotechnology) and AffiniPure F(ab 0 ) 2 fragment goat anti-human IgM (Jackson Immunoresearch Laboratories) were used for stimulation of K46 and Ramos cells, respectively. The anti-GFP antibody and the rabbit anti-Shc antibodies were purchased from Boehringer and Transduction Laboratories, respectively. Goat-anti-rabbit IgG conjugated with horseradish peroxidase (HRP) and goat anti-mouse IgG-HRP were purchased from Pierce.
Stimulation of B cells with anti-Ig antibodies
DT40 cells were stimulated as described (Brummer et al., 2002) . K46 and Ramos cells were stimulated in eppendorf tubes with 10 mg goat anti-mouse IgG and 13 mg goat anti-human IgM F(ab 0 ) 2 fragments, respectively. After the indicated incubation times, cells were collected by centrifugation for 10 s and lysed in 200 ml of ice-cold lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Nonidet P40, 137.5 mM NaCl, 1% glycerol, 2 mM sodium orthovanadate and 0.5 mM EDTA (pH 8.0)) supplemented with protease inhibitors (0.1 mg/ml aprotinine, 0.5 mg/ml leupeptin, 1 mM AEBSF). Total cellular lysates (TCL) were processed as described (Brummer et al., 2002) .
MEK-inhibitor experiments
DT40 cells were adjusted in their culture medium to a density of 10 7 cells/ml. Subsequently, DMSO (Roth) as vehicle control or the MEK-inhibitor U0126 (Promega) were added to the cell suspension to the indicated final concentration. The cells were collected after 25 min of incubation at 371C, stimulated and processed to TCL.
SDS-PAGE and Western blot analysis
Samples were separated on 8, 10 or 12% SDS-PAGE gels as indicated, and Western Blot analyses were performed using standard procedures and the enhanced chemiluminescence (ECL) system (Amersham).
Protein dephosphorylation on membrane with l-Phosphatase (l-PPase) TCL were separated by SDS-PAGE and transferred to a PVDF membrane as described (Brummer et al., 2002) . Subsequently, the membrane was cut into three pieces, each carrying an identical set of lysates. The membranes were equilibrated with 20 ml of l-PPase buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% Brij 58 and 2 mM MnCl 2 ) for 5 min. The equilibration solution was replaced by 20 ml of l-PPase buffer (buffer control) or 20 ml of l-PPase buffer supplemented with 4.000 U l-PPase (New England Biolabs) and the membranes were incubated at room temperature (RT) overnight. After three washes with washing buffer (PBS, 0.1% Tween 20), the membranes were blocked and B-Raf was detected as indicated. Successful dephosphorylation of proteins was confirmed by using phosphospecific antibodies (data not shown).
Immunoprecipitation and in vitro kinase assays
Confluent culture dishes (10-cm diameter) of COS-7 transfectants expressing either EGFP or EGFP/B-RafCT were lysed in RIPA buffer (50 mM HEPES pH7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaF, 10 mM sodium pyrophosphate and 5 mM EDTA) supplemented with protease inhibitors (0.1 mg/ml aprotinine, 0.5mg/ml leupeptin and 1 mM AEBSF). Cleared TCL were subsequently incubated with 2 mg anti-GFP antibodies on ice for 1 h. This incubation was followed by addition of Protein-G Sepharose beads (4 FastFlow; Pharmacia) and further incubation with gentle inversion at 41C for 12 h. The beads were washed three times with 500 ml of RIPA buffer, three times with 500 ml of ERK-kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 2 mM dithiothreitol and 0.01% Brij 35 or Brij 58) and stored at À801C. An appropriate amount of the beads was diluted in ERK-kinase buffer, mixed with 10 mCi [g-33 P]ATP (AmershamPharmacia) and activated, recombinant ERK2 (New England Biolabs). The reaction was performed at 301C for 30 min and stopped by addition of one volume of 2 Â sample buffer followed by boiling for 5 min. Samples were size-separated by 10% SDS-PAGE. The gels were dried and subjected to autoradiography.
For isolation of B-Raf, 2 Â 10 7 DT40 cells were lysed in RIPA buffer as described. TCL were precleared with protein-G sepharose beads with gentle inversion at 41C for 1 h. Subsequently, the precleared TCL were incubated with 2 mg anti-B-Raf H-145 antibodies and B-Raf containing immune complexes were purified and phosphorylated by activated, recombinant ERK2, as described above.
